...
首页> 外文期刊>Herz >Vascular access site complications after percutaneous transfemoral aortic valve implantation.
【24h】

Vascular access site complications after percutaneous transfemoral aortic valve implantation.

机译:经皮经股动脉主动脉瓣植入术后血管通路部位并发症。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND AND PURPOSE: Transcatheter aortic valve implantation (TAVI) is a rapidly emerging treatment option for patients with aortic valve stenosis and high surgical risk. Different access routes have been proposed for TAVI including transapical, transsubclavian and transfemoral, with percutaneous transfemoral being the preferred because least invasive and nonsurgical. However, vascular access site complications due to the large-bore delivery catheters remain an important clinical issue, particularly with respect to the elderly patient collective typically considered for TAVI. In the study, the authors analyzed their 4-year TAVI experience with respect to vascular complications and their management in patients undergoing completely percutaneous transfemoral TAVI procedures. PATIENTS AND METHODS: Since 2006, TAVI was performed in 101 consecutive patients at the West German Heart Center Essen. 33 patients underwent transapical TAVI, eight patients transfemoral TAVI with surgical access or closure, and 60 patients percutaneous transfemoral TAVI using two commercially available prosthetic valve devices. RESULTS: Completely percutaneous TAVI was technically successful in all but one patient with malpositioning in the aortic arch during valve retrieval. There was no intraprocedural death and 30-day mortality was 12% (7/60). Vascular access site complications occurred in 19 patients (32%), necessitating surgical repair in six of them (10%). Complications included retroperitoneal hematoma (n = 2), iliac or femoral artery dissection (n = 10), (pseudo)aneurysm formation (n = 3), and closure device-induced vessel stenosis/ occlusion (n = 6). Of these, 13 cases could be managed either conservatively (n = 5) or by contralateral endovascular treatment (n = 8). CONCLUSION: Completely percutaneous TAVI has a high acute success rate with low intraprocedural and 30-day mortality. The patient collective appears to be prone to vascular complications which remain an important limitation of this novel technique. Although conservative or endovascular management is possible in the majority of cases, further technological developments are obliged to reduce the vascular complication rate.
机译:背景与目的:经导管主动脉瓣植入术(TAVI)是一种主动脉瓣狭窄和高手术风险患者的快速出现的治疗选择。对于TAVI,已经提出了不同的进入途径,包括经心尖,经锁骨下和经股动脉,其中经皮经股动脉是优选的,因为其具有最小的侵入性和非手术性。然而,由于大口径输送导管引起的血管进入部位并发症仍然是重要的临床问题,特别是对于通常考虑TAVI的老年患者。在这项研究中,作者分析了他们在完全经皮经股静脉TAVI手术中患者在血管并发症和治疗方面的4年经验。患者与方法:自2006年以来,在西德埃森心脏中心连续对101例患者进行了TAVI治疗。 33例患者行经心尖TAVI,8例经手术或封闭手术的股动脉TAVI,60例患者使用2种市售的人工瓣膜经皮TAVI。结果:除一名患者外,在瓣膜修复过程中主动脉弓位置不正确的患者中,完全经皮TAVI在技术上取得了成功。没有手术中死亡,30天死亡率为12%(7/60)。血管通路部位并发症发生在19例患者中(32%),其中有六例需要手术修复(10%)。并发症包括腹膜后血肿(n = 2),或股动脉解剖(n = 10),(假性)动脉瘤形成(n = 3)以及闭合装置引起的血管狭窄/闭塞(n = 6)。其中13例可以保守治疗(n = 5)或通过对侧血管内治疗(n = 8)进行治疗。结论:完全经皮TAVI具有较高的急性成功率,较低的术中死亡率和30天死亡率。患者集体似乎易于出现血管并发症,这仍然是该新技术的重要局限性。尽管在大多数情况下可以进行保守或血管内治疗,但仍需要进一步的技术发展来降低血管并发症的发生率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号